Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.00758902510215992 -0.00108414644316567 -0.00108414644316567 -0.00108414644316567
Stock impact report

Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet

Intercept Pharmaceuticals, Inc. (ICPT) 
Last intercept pharmaceuticals, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.interceptpharma.com/investor-relations
Company Research Source: GlobeNewswire
NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the positive results from the interim analysis of the Phase 3 REGENERATE study of obeticholic acid (OCA) in patients with fibrosis due to nonalcoholic steatohepatitis (NASH) have been published in The Lancet. This is the first peer-reviewed publication of positive results from a pivotal study evaluating an investigational therapy for NASH. “The first positive Phase 3 study results in NASH represent a real watershed moment for the hepatology field,” said Zobair M. Younossi, M.D., Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus, Chair of the REGENERATE Steering Committee and a lead author of the publication. “The antifibrotic efficacy observed with just 18 months of OCA treatment in REGENERATE Show less Read more
Impact Snapshot
Event Time:
ICPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ICPT alerts
Opt-in for
ICPT alerts

from News Quantified
Opt-in for
ICPT alerts

from News Quantified